Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis

Phase 1

Completed

• Conditions: End Stage Renal Disease on Hemodialysis
• Interventions: Drug: Difelikefalin Injection

• Registration Number: NCT05885763
• Lead Sponsor: Vifor Fresenius Medical Care Renal Pharma

Brief Summary

This is a Phase 1, single-arm, open-label study to evaluate the safety, PK, and tolerability of a repeated (3 times weekly) dose of difelikefalin administered as IV bolus injections to adult Chinese HD subjects. Treatment period is one week and there is a safety follow-up period of 1 week.

Detailed Description

This is a Phase 1, single-arm, open-label study to evaluate the safety, PK, and tolerability of a repeated (3 times weekly) dose of difelikefalin administered as IV bolus injections to adult Chinese HD subjects.

Total study duration for a single subject is up to 5 weeks including a screening period of up to 3 weeks, a treatment period of 1 week, and a safety follow-up period of 1 week.

The duration of PK sampling is 12 days.

The primary objective of the study is to evaluate the PK profile of a repeated (3 times weekly) dose of difelikefalin in Chinese HD subjects over a 1-week treatment period.

Study Timeline

• Study First Submitted: 2023-05-17
• Study First Submitted QC: 2023-06-01
• Study First Posted: 2023-06-02
• Study Start: 2023-06-26
• Primary Completion: 2023-10-09
• Study Completion: 2023-10-09
• Results First Submitted: 2025-01-21
• Status Verified: 2025-02
• Results First Submitted QC: 2025-02-13
• Last Update Submitted: 2025-02-13
• Results First Posted: 2025-02-14
• Last Update Posted: 2025-02-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• End-stage renal disease (ESRD) subjects who have been on HD for at least 3 months before enrolment in the study and are currently on HD 3 times per week.

• Subjects with a prescription dry body weight between 40 and 100 kg, inclusive.

• If female, is not pregnant, or nursing

• If female:

  1. Is surgically sterile; or
  2. Has been amenorrhoeic for at least 1 year and is over the age of 55 years; or
  3. Has a negative serum pregnancy test within 7 days before first dose of investigational product, and agrees to use adequate contraceptive precautions (e.g., hormonal contraceptives, barrier with spermicide, intrauterine device, vasectomised partner, or abstinence) from the time of informed consent until 7 days after the last dose of investigational product.

• If male, agrees not to donate sperm from the first dose of investigational product administration (Day 1) until 7 days after last dosing, and agrees to use a condom with spermicide or abstain from heterosexual intercourse during the study until 7 days after the last dose of investigational product.

Exclusion Criteria

• Planned or anticipated to receive a kidney transplant during the study.
• Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) greater than 2.5 × the reference upper limit of normal (ULN), or bilirubin (total) greater than 4 × the ULN at screening.
• Subjects with severe hepatic impairment (Child-Pugh Class C).
• Known history of allergic reaction to opiates such as hives. Note: Side effects related to the use of opioids such as constipation or nausea would not exclude the subjects from the study.
• Subject has known hypersensitivity to the study intervention or any component of the investigational product formulation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1-week, single arm, open label treatment phase	Difelikefalin Injection	-

Primary Outcome Measures

Name	Time	Method
AUCinf - Dose 1	1 week	AUCinf = AUC from time zero to infinity
AUCextrap(%) - Dose 1	1 week	AUCextrap(%) = percentage of AUCinf based on extrapolation
t½ - Dose 1	1 week	t½ = elimination half-life
Clearance - Dose 1	1 week	Clearance = the volume of blood or plasma that can be freed of a specified constituent in a specified time by its excretion into the urine through the kidneys
Evaluation of the PK Profile of Difelikefalin - Tmax - Dose 3	1 week	Tmax = Time to reach maximum observed plasma concentration
Evaluation of the PK Profile of Difelikefalin - Cmax - Dose 1	1 week	Cmax = Maximum (peak) observed plasma concentration
Evaluation of the PK Profile of Difelikefalin - Tmax - Dose 1	1 week	Tmax = Time to reach maximum observed plasma concentration
Evaluation of the PK Profile of Difelikefalin - AUC0-t - Dose 1	1 week	AUC0-t = Area under the concentration-versus-time curve (AUC) from time zero to time "t"
Vz - Dose 1	1 week	Vz = volume of distribution
Evaluation of the PK Profile of Difelikefalin - Cmax - Dose 3	1 week	Cmax = Maximum (peak) observed plasma concentration
Evaluation of the PK Profile of Difelikefalin - AUC0-t - Dose 3	1 week	AUC0-t = Area under the concentration-versus-time curve (AUC) from time zero to time "t"
AUCinf - Dose 3	1 week	AUCinf = AUC from time zero to infinity
AUCextrap(%) - Dose 3	1 week	AUCextrap(%) = percentage of AUCinf based on extrapolation
t½ - Dose 3	1 week	t½ = elimination half-life

Trial Locations

Locations (4)

Investigator Site 3; 🇨🇳 Beijing, China

Investigator Site 1; 🇨🇳 Beijing, China

Investigator Site 2; 🇨🇳 Beijing, China

Investigator Site 4; 🇨🇳 Shijiazhuang, China